Cyclopharm Lands Immediate 11-Site Technegas Deployment with University Hospitals
Cyclopharm has landed a major US expansion deal with University Hospitals Cleveland, deploying Technegas® across 11 sites simultaneously and boosting its recurring revenue base in the Midwest.
- Immediate system-wide installation at 11 University Hospitals sites
- Strengthens Cyclopharm’s US Midwest footprint
- Recurring revenue from functional lung ventilation imaging
- University Hospitals is a top-tier academic health system
- Technegas® expanding beyond pulmonary embolism diagnosis
Immediate 11-Site Technegas Deployment in Cleveland
Cyclopharm Limited (ASX:CYC) has secured a landmark agreement with University Hospitals (UH) in Cleveland, Ohio, for the immediate installation of its Technegas® lung imaging system across 11 clinical locations. Unlike typical staggered rollouts, UH has committed to a system-wide deployment, with all installations scheduled to occur within the next few weeks. The readiness of all sites prior to signing underscores UH’s confidence in the technology and expedites Cyclopharm’s revenue generation from these locations.
Expanding Presence in a Prestigious US Health Network
University Hospitals is a highly regarded academic health system with a 160-year legacy, serving over one million patients annually and employing more than 32,000 caregivers. Anchored by the University Hospitals Cleveland Medical Center, a major academic medical complex and primary teaching hospital of Case Western Reserve University, UH is consistently ranked among the top US hospitals. This deal significantly enhances Cyclopharm’s portfolio of high-quality US reference sites and extends its reach in the Midwest region.
Commercial and Strategic Implications for Cyclopharm
The immediate, system-wide nature of the agreement validates Cyclopharm’s enterprise adoption strategy in the US market. Each installed site will generate recurring revenue streams from patient procedures using Technegas®, including consumables and service fees that scale with volume growth. This deal deepens Cyclopharm’s recurring revenue base and demonstrates the clinical utility of Technegas® at enterprise scale.
Managing Director James McBrayer highlighted the significance of UH’s simultaneous commitment across multiple sites, calling it a direct reflection of the recognised clinical value Technegas® delivers. He also pointed to the broader potential of Technegas® beyond pulmonary embolism diagnosis, with ongoing research into applications for COPD, asthma, pulmonary hypertension, and interventional lung procedures. UH’s strong research credentials position it as a pivotal national reference site for showcasing Technegas® to peer institutions, potentially accelerating adoption across the US healthcare system.
Technegas® Technology and Future Prospects
Technegas® is a radiopharmaceutical product used for functional lung ventilation imaging, inhaled by patients to provide detailed views of lung function via gamma or SPECT cameras. Its ultra-fine particle dispersion offers advantages in uniform lung distribution, making it a promising platform for next-generation quantitative and AI-driven lung imaging. While currently approved in the US primarily for pulmonary embolism evaluation, ongoing clinical research is investigating its use in other respiratory conditions and interventional applications.
Bottom Line?
Cyclopharm’s rapid system-wide deployment with University Hospitals Cleveland marks a pivotal US expansion milestone, but execution and broader clinical adoption remain key to sustaining momentum.
Questions in the middle?
- How quickly will Cyclopharm convert installations into recurring revenue growth across the UH network?
- Will University Hospitals’ role as a national reference site accelerate Technegas® adoption in other US health systems?
- How soon might regulatory approvals expand Technegas® indications beyond pulmonary embolism in the US?
